{{Drugbox
| IUPAC_name =  3-[(3a''R'',4''R'',5''S'',7a''S'')-5-{(1''R'')-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-2''H''-isoindol-2-yl]cyclopent-2-en-1-one
| image = Serlopitant.svg
| width = 275

<!--Clinical data-->
| tradename =
| pregnancy_category =
| legal_status =
| routes_of_administration = [[Oral administration|By mouth]]

<!--Pharmacokinetic data-->
| bioavailability =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number = 860642-69-9
| ATC_prefix = None
| ATC_suffix =
| PubChem = 23653789
| ChemSpiderID = 24686685
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 277V92K32B
| ChEMBL = 447955
| KEGG = D09378

<!--Chemical data-->
| C=29 | H=28 | F=7 | N=1 | O=2 
| molecular_weight = 555.527 g/mol
| smiles = C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@H]2CC[C@@H]3CN(C[C@H]3[C@@H]2C4=CC=C(C=C4)F)C5=CC(=O)CC5
| StdInChI = 1S/C29H28F7NO2/c1-16(19-10-20(28(31,32)33)12-21(11-19)29(34,35)36)39-26-9-4-18-14-37(23-7-8-24(38)13-23)15-25(18)27(26)17-2-5-22(30)6-3-17/h2-3,5-6,10-13,16,18,25-27H,4,7-9,14-15H2,1H3/t16-,18-,25-,26+,27+/m1/s1
| StdInChIKey = FLNYCRJBCNNHRH-OIYLJQICSA-N
}}

'''Serlopitant''' ([[International nonproprietary name|INN]],<ref name="INN">{{cite web | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 62 | url = http://www.who.int/medicines/publications/druginformation/innlists/RL62.pdf | publisher = World Health Organization | accessdate = 17 November 2016 | pages = 261–2 | date = 2009}}</ref> codenamed '''VPD-737''') is a [[drug]] which acts as an [[NK1 receptor|NK<sub>1</sub> receptor]] [[receptor antagonist|antagonist]]. It was assessed in [[clinical trials]] for the treatment of [[urinary incontinence]] and [[overactive bladder]], but while it was superior to [[placebo]] it provided no advantage over existing approved drugs, and was not approved for further development for this indication.<ref>{{cite journal | last1 = Frenkl | first1 = TL | last2 = Zhu | first2 = H | last3 = Reiss | first3 = T | last4 = Seltzer | first4 = O | last5 = Rosenberg | first5 = E | last6 = Green | first6 = S | title = A Multicenter, Double-Blind, Randomized, Placebo Controlled Trial of a Neurokinin-1 Receptor Antagonist for Overactive Bladder | journal = The Journal of Urology | date = August 2010 | volume = 184 | issue = 2 | pages = 616–22 | doi = 10.1016/j.juro.2010.03.147 | pmid=20639026}}</ref><ref>{{cite journal | last1 = Payton | first1 = S | title = Urinary Incontinence: Neurokinin Receptor Antagonist Inferior to Tolterodine for OAB | journal = Nature Reviews Urology | date = August 2010 | volume = 7 | issue = 8 | page = 418 | doi = 10.1038/nrurol.2010.105 | pmid = 20726068}}</ref> Serlopitant is now undergoing clinical trials for the treatment of chronic pruritus (itch)<ref>[http://www.medscape.com/viewarticle/885765#vp_2]</ref>

== See also ==
* [[NK1 receptor antagonist|NK<sub>1</sub> receptor antagonist]]

== References ==
{{Reflist}}

{{Neurokinin receptor modulators}}

[[Category:NK1 receptor antagonists]]
[[Category:Trifluoromethyl compounds]]
[[Category:Fluoroarenes]]


{{genito-urinary-drug-stub}}